Guerbet SA (EPA:GBT)
France · Delayed Price · Currency is EUR | Market Cap | 126.15M -51.4% |
| Revenue (ttm) | 798.67M -6.2% |
| Net Income | -108.33M |
| EPS | -8.59 |
| Shares Out | 12.62M |
| PE Ratio | n/a |
| Forward PE | 4.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,429 |
| Average Volume | 14,975 |
| Open | 10.04 |
| Previous Close | 10.00 |
| Day's Range | 9.94 - 10.06 |
| 52-Week Range | 8.01 - 23.70 |
| Beta | 0.99 |
| RSI | 42.85 |
| Earnings Date | Sep 15, 2026 |
About Guerbet
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; ... [Read more]
Financial Performance
Financial StatementsNews
Q1 2026 revenue
Q1 2026 revenue Quarterly activity Revenue: €177.4m, up 2.6% at CER 1 and on a like-for-like basis 2 Increase driven by EMEA (+4.5%), with an improvement in the situation in France, and by Asia (+6.0%...